Search / 94 results found

from
to
  • Updated

RADNOR, Pa., Oct. 12, 2021 /PRNewswire/ -- NRx Pharmaceuticals (Nasdaq: NRXP), today announced that a revised Investigational New Drug module on the manufacturing of ZYESAMI™ (aviptadil) was submitted to the US Food and Drug Administration (FDA), containing documentation that confirmed Nephron Pharmaceuticals, Inc. is prepared to supply ZYESAMI on a commercial scale. This module will now be used as part of the FDA's rolling review process supporting the New Drug Application for ZYESAMI.

  • Updated

PITTSBURGH, Sept. 28, 2021 /PRNewswire/ -- EQT Corporation (NYSE: EQT) (the Company or EQT) today announced the pricing of an underwritten public offering of 25,930,000 shares of its common stock by certain shareholders at a price to the public of $20.00 per share (the Offering). Such selling shareholders, who had received the shares as a part of the Company's acquisition of Alta Resources Development, LLC's upstream and midstream subsidiaries, have granted the underwriters a 30-day option to purchase up to an additional 3,889,500 shares of the Company's common stock. EQT will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares being offered by the selling shareholders. The Offering is expected to close on October 1, 2021, subject to customary closing conditions.

  • Updated

PITTSBURGH, Sept. 28, 2021 /PRNewswire/ -- EQT Corporation (NYSE: EQT) (the Company or EQT) today announced the commencement of an underwritten public offering of 25,930,000 shares of its common stock by certain shareholders who received the shares as a part of the Company's acquisition of Alta Resources Development, LLC's upstream and midstream subsidiaries (the Offering). Such selling shareholders intend to grant the underwriters a 30-day option to purchase up to an additional 3,889,500 shares of the Company's common stock. EQT will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares being offered by the selling shareholders. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.